AbbVie reports 14.7-month median survival for Temab-A combination in early-stage colorectal cancer trial

Bitget2026/10/18 22:11

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

AbbVie will present updated solid-tumor study results at the ESMO Congress in Madrid, October 23-27, 2026.
Temab-A with bevacizumab showed longer median survival than standard care in previously treated colorectal cancer, supporting an ongoing Phase 3 trial.
In lung cancer, Temab-A showed tumor responses, including activity against brain metastases; no new safety signals emerged in the brain-metastases analysis.
The investigational drug recently received FDA Breakthrough Therapy designations for colorectal cancer and non-small cell lung cancer.
ABBV-706 showed tumor responses in previously treated small cell lung cancer, supporting continued Phase 3 evaluation against standard care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610181810PR_NEWS_USPR_____CG74688) on October 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AbbVie reports 14.7-month median survival for Temab-A combination in early-stage colorectal cancer trial

You may also like

Crypto prices